Scientific Opinion on the extension of use for DHA and EPA-rich algal oil from Schizochytrium sp. as a Novel Food ingredient

EFSA Journal

Volumn 12, Issue 10, 2014, Pages

[No Author Info available]

Author keywords

algal oil; docosahexaenoic acid (DHA); eicosapentaenoic acid (EPA); ingredient; novel food; Schizochytrium sp

Indexed keywords

EID: 84957933987     PISSN: None     EISSN: 18314732     Source Type: Journal    
DOI: 10.2903/j.efsa.2014.3843     Document Type: Article

References (37)

1. ACNFP (Advisory Committee on Novel Foods and Processes), 2012. Opinion on an application under the Novel Food Regulation for a DHA and EPA rich oil from the microalgae Schizochytrium. 9 December 2011. NFU 786, 10 pp.
2. ACS (American Cancer Society), 2011. Global Cancer Facts & Figures 2nd Edition. American Cancer Society, Atlanta, GA., 60 pp.
3. Astorg P, 2004. Dietary N-6 and N-3 polyunsaturated fatty acids and prostate cancer risk: a review of epidemiological and experimental evidence. Cancer Causes & Control, 15, 367–386.
4. BfR (Bundesinstitut für Risikobewertung), 2009. Überprüfung der gesundheitlichen Unbedenklichkeit der Aufnahme von Docosahexaensäure (DHA) und Eicosapentaensäure (EPA) bzw. Omega-3-Fettsäuren im Allgemeinen. Verfahren nach Artikel 8 der Verordnung (EG) Nr. 1925/2006 des Europäischen Parlaments und des Rates vom 20. Dezember 2006 über den Zusatz von Vitaminen, Mineralstoffen sowie bestimmten anderen Stoffen zu Lebensmitteln. 11 pp.
5. Brasky TM, Till C, White E, Neuhouser ML, Song X, Goodman P, Thompson IM, King IB, Albanes D and Kristal AR, 2011. Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial. American Journal of Epidemiology, 173, 1429–1439.
6. Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL, Jr., Goodman GE, Minasian LM, Parnes HL, Klein EA and Kristal AR, 2013. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. Journal of the National Cancer Institute, 105, 1132–1141.
7. Chavarro JE, Stampfer MJ, Li H, Campos H, Kurth T and Ma J, 2007. A prospective study of polyunsaturated fatty acid levels in blood and prostate cancer risk. Cancer Epidemiology, Biomarkers and Prevention, 16, 1364–1370.
8. Chavarro JE, Stampfer MJ, Hall MN, Sesso HD and Ma J, 2008. A 22-y prospective study of fish intake in relation to prostate cancer incidence and mortality. American Journal of Clinical Nutrition, 88, 1297–1303.
9. Chua ME, Sio MC, Sorongon MC and Dy JS, 2012. Relationship of dietary intake of omega-3 and omega-6 Fatty acids with risk of prostate cancer development: a meta-analysis of prospective studies and review of literature. Prostate Cancer, 2012, 826254.
10. Chua ME, Sio MC, Sorongon MC and Morales ML, Jr., 2013. The relevance of serum levels of long chain omega-3 polyunsaturated fatty acids and prostate cancer risk: A meta-analysis. Canadian Urological Association Journal, 7, E333–343.
11. Crowe FL, Allen NE, Appleby PN, Overvad K, Aardestrup IV, Johnsen NF, Tjonneland A, Linseisen J, Kaaks R, Boeing H, Kroger J, Trichopoulou A, Zavitsanou A, Trichopoulos D, Sacerdote C, Palli D, Tumino R, Agnoli C, Kiemeney LA, Bueno-de-Mesquita HB, Chirlaque MD, Ardanaz E, Larranaga N, Quiros JR, Sanchez MJ, Gonzalez CA, Stattin P, Hallmans G, Bingham S, Khaw KT, Rinaldi S, Slimani N, Jenab M, Riboli E and Key TJ, 2008. Fatty acid composition of plasma phospholipids and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition. American Journal of Clinical Nutrition, 88, 1353–1363.
12. Dahm CC, Gorst-Rasmussen A, Crowe FL, Roswall N, Tjonneland A, Drogan D, Boeing H, Teucher B, Kaaks R, Adarakis G, Zylis D, Trichopoulou A, Fedirko V, Chajes V, Jenab M, Palli D, Pala V, Tumino R, Ricceri F, Van Kranen H, Bueno-de-Mesquita HB, Quiros JR, Sanchez MJ, Lujan-Barroso L, Larranaga N, Chirlaque MD, Ardanaz E, Johansson M, Stattin P, Khaw KT, Wareham N, Wark PA, Norat T, Riboli E, Key TJ and Overvad K, 2012. Fatty acid patterns and risk of prostate cancer in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition. American Journal of Clinical Nutrition, 96, 1354–1361.
13. EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2010a. Scientific Opinion the substantiation of a health claim related to docosahexaenoic acid (DHA) and maintenance of normal (fasting) blood concentrations of triglycerides (ID 533, 691, 3150), protection of blood lipids from oxidative damage (ID 630), contribution to the maintenance or achievement of a normal body weight (ID 629), brain, eye and nerve development (ID 627, 689, 704, 742, 3148, 3151), maintenance of normal brain function (ID 565, 626, 631, 689, 690, 704, 742, 3148, 3151), maintenance of normal vision (ID 627, 632, 743, 3149) and maintenance of normal spermatozoa motility (ID 628) pursuant to Article 13(3) of Regulation (EC) no 1924/2006. EFSA Journal 2010;8(10):1734, 27 pp. doi:10.2903/j.efsa.2010.1734.
14. EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2010b. Scientific Opinion on the substantiation of health claims related to eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and maintenance of normal cardiac function (ID 504, 506, 516, 527, 538, 703, 1128, 1317, 1324, 1325), maintenance of normal blood glucose concentrations (ID 566), maintenance of normal blood pressure (ID 506, 516, 703, 1317, 1324), maintenance of normal blood HDL-cholesterol concentrations (ID 506), maintenance of normal (fasting) blood concentrations of triglycerides (ID 506, 527, 538, 1317, 1324, 1325), maintenance of normal blood LDL-cholesterol concentrations (ID 527, 538, 1317, 1325, 4689), protection of the skin from photo-oxidative (UV-induced) damage (ID 530), improved absorption of EPA and DHA (ID 522, 523), contribution to the normal function of the immune system by decreasing the levels of eicosanoids, arachidonic acid-derived mediators and pro-inflammatory cytokines (ID 520, 2914), and “immunomodulating agent” (4690) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2010;8(10):1796, 32 pp. doi:10.2903/j.efsa.2010.1796.
15. EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2012. Scientific Opinion on the Tolerable Upper Intake Level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA Journal 2012;10(7):2815, 48 pp. doi:10.2903/j.efsa.2012.2815.
16. EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2014. Scientific Opinion on health benefits of seafood (fish and shellfish) consumption in relation to health risks associated with exposure to methylmercury. EFSA Journal 2014;12(7):3761, 80 pp. doi:10.2903/j.efsa.2014.3761.
17. FSA (Food Standards Agency), 2012. DHA and EPA rich oil from the microalgae Schizochytrium. Letter to DSM Nutritional Lipids. 6 July 2012. NFU 786, 5 pp.
18. Godley PA, Campbell MK, Gallagher P, Martinson FE, Mohler JL and Sandler RS, 1996. Biomarkers of essential fatty acid consumption and risk of prostatic carcinoma. Cancer Epidemiology, Biomarkers and Prevention, 5, 889–895.
19. Harvei S, Bjerve KS, Tretli S, Jellum E, Robsahm TE and Vatten L, 1997. Prediagnostic level of fatty acids in serum phospholipids: omega-3 and omega-6 fatty acids and the risk of prostate cancer. International Journal of Cancer, 71, 545–551.
20. Iso H, Kubota Y and Japan Collaborative Cohort Study for Evaluation of C, 2007. Nutrition and disease in the Japan Collaborative Cohort Study for Evaluation of Cancer (JACC). Asian Pacific Journal of Cancer Prevention, 8 Suppl, 35–80.
21. Kobayashi N, Barnard RJ, Henning SM, Elashoff D, Reddy ST, Cohen P, Leung P, Hong-Gonzalez J, Freedland SJ, Said J, Gui D, Seeram NP, Popoviciu LM, Bagga D, Heber D, Glaspy JA and Aronson WJ, 2006. Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clinical Cancer Research, 12, 4662–4670.
22. Larsson SC, Kumlin M, Ingelman-Sundberg M and Wolk A, 2004. Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. American Journal of Clinical Nutrition, 79, 935–945.
23. Leitzmann MF, Stampfer MJ, Michaud DS, Augustsson K, Colditz GC, Willett WC and Giovannucci EL, 2004. Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancer. American Journal of Clinical Nutrition, 80, 204–216.
24. Mannisto S, Pietinen P, Virtanen MJ, Salminen I, Albanes D, Giovannucci E and Virtamo J, 2003. Fatty acids and risk of prostate cancer in a nested case-control study in male smokers. Cancer Epidemiology, Biomarkers and Prevention, 12, 1422–1428.
25. Manson JE, Bassuk SS, Lee IM, Cook NR, Albert MA, Gordon D, Zaharris E, Macfadyen JG, Danielson E, Lin J, Zhang SM and Buring JE, 2012. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemporary Clinical Trials, 33, 159–171.
26. Martek Biosciences Corporation, 2010. Application for the authorisation of DHA and EPA-rich algal oil from Schyzochytrium sp. submitted pursuant to Regulation (EC) No 258/97 of the European Parliament and the Council of the 27th January 1997 concerning novel foods and novel food ingredients. 63 pp.
27. Newcomer LM, King IB, Wicklund KG and Stanford JL, 2001. The association of fatty acids with prostate cancer risk. Prostate, 47, 262–268.
28. Norrish AE, Skeaff CM, Arribas GL, Sharpe SJ and Jackson RT, 1999. Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case-control study. British Journal of Cancer, 81, 1238–1242.
29. Park SY, Murphy SP, Wilkens LR, Henderson BE and Kolonel LN, 2007. Fat and meat intake and prostate cancer risk: the multiethnic cohort study. International Journal of Cancer, 121, 1339–1345.
30. Park SY, Wilkens LR, Henning SM, Le Marchand L, Gao K, Goodman MT, Murphy SP, Henderson BE and Kolonel LN, 2009. Circulating fatty acids and prostate cancer risk in a nested case-control study: the Multiethnic Cohort. Cancer Causes & Control, 20, 211–223.
31. Schuurman AG, Van den Brandt PA, Dorant E, Brants HA and Goldbohm RA, 1999. Association of energy and fat intake with prostate carcinoma risk: results from The Netherlands Cohort Study. Cancer, 86, 1019–1027.
32. Shannon J, O'Malley J, Mori M, Garzotto M, Palma AJ and King IB, 2010. Erythrocyte fatty acids and prostate cancer risk: a comparison of methods. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 83, 161–169.
33. Sorongon-Legaspi MK, Chua M, Sio MC and Morales M, Jr., 2013. Blood level omega-3 Fatty acids as risk determinant molecular biomarker for prostate cancer. Prostate Cancer, 2013, 875615.
34. Szymanski KM, Wheeler DC and Mucci LA, 2010. Fish consumption and prostate cancer risk: a review and meta-analysis. American Journal of Clinical Nutrition, 92, 1223–1233.
35. Ukoli FA, Akumabor PN, Oguike TC, Dent LL, Beech D and Osime U, 2009. The association of plasma fatty acids with prostate cancer risk in Nigerians. Ethnicity & Disease, 19, 454–461.
36. Ukoli FA, Fowke JH, Akumabor P, Oguike T, Taher KA, Murff HJ, Amaefuna ER, Kittles R, Ahaghotu C, Osime U and Beech DJ, 2010. The association of plasma fatty acids with prostate cancer risk in African Americans and Africans. Journal of Health Care for the Poor and Underserved, 21, 127–147.
37. Wallstrom P, Bjartell A, Gullberg B, Olsson H and Wirfalt E, 2007. A prospective study on dietary fat and incidence of prostate cancer (Malmo, Sweden). Cancer Causes & Control, 18, 1107–1121.